drugset / Trial / NCT03574584

A Research Study of NNC0165-1562 and Semaglutide in People Who Are Overweight or Obese

NCT03574584

Phase 1 Completed 37 enrolled Novo Nordisk A/S
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The study is investigating new medicines for weight control in people with high body weight. The study looks at how the study medicines work in the body. Participants will get semaglutide and either NNC0165-1562 or "dummy" medicine -which treatment participants get is decided by chance. Participants will get 2 injections per week for 5 months. A study nurse at the clinic will inject the medicine with a thin needle in a skin fold in the stomach. The study will last for about 7 months. Participants will have 27 visits to the clinic.

Timeline

Start
2018-06-18
Primary completion
2019-07-27
Completion
2019-07-27

Drugs

EvaluationDrugModalityDoseRoute
Subject NNC0165-1562 Unknown Subcutaneous
Subject Semaglutide Peptide Subcutaneous